Sanyal, Arun J. http://orcid.org/0000-0001-8682-5748
Shankar, Sudha S.
Yates, Katherine P.
Bolognese, James
Daly, Erika
Dehn, Clayton A.
Neuschwander-Tetri, Brent http://orcid.org/0000-0002-8520-7398
Kowdley, Kris
Vuppalanchi, Raj http://orcid.org/0000-0003-0637-1577
Behling, Cynthia
Tonascia, James
Samir, Anthony http://orcid.org/0000-0002-7801-8724
Sirlin, Claude http://orcid.org/0000-0002-6639-9072
Sherlock, Sarah P.
Fowler, Kathryn
Heymann, Helen
Kamphaus, Tania N.
Loomba, Rohit http://orcid.org/0000-0002-4845-9991
Calle, Roberto A. http://orcid.org/0000-0001-6577-5657
Article History
Received: 18 January 2023
Accepted: 8 August 2023
First Online: 7 September 2023
Competing interests
: A.J.S. has stock options in Genfit, Tiziana, Indalo, Durect, Inversago and Galmed. He has served as a consultant to AstraZeneca, Salix, Tobira, Takeda, Janssen, Gilead, Terns, Merck, Madrigal, NGM Biopharmaceuticals, Sagimet, Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Hemoshear, Novartis, Inventiva, Enyo, Akero, 89Bio, Novo Nordisk, Pfizer, Amgen, Genentech, Regeneron, Alnylam, Hanmi, LG Chem, Histoindex, Thera Technologies, Intercept, Target-RWE, Surrozen, Zydus, Path AI, Exhalenz and Genfit. His institution has received grant support from Gilead, Salix, Tobira, Bristol Myers Squibb, Pfizer, Intercept, Merck, AstraZeneca, Malinckrodt and Novartis. He receives royalties from Elsevier and UptoDate. He recused himself from the analysis and interpretation of NIS4. S.S.S. is an employee of AstraZeneca. K.P.Y. has no conflicts to report. J.B. is a paid consultant for Cytel. E.D. is an employee of Cytel. C.A.D. is a volunteer consultant for NIMBLE (P Value Communications, LLC). B.N.-T. is a consultant or advisor for Akero, Alimentiv, Allergan, Allysta, Alnylam, Amgen, Arrowhead, Axcella, Boehringer Ingelheim, Bristol Myers Squibb, Coherus, Cymabay, Durect, Enanta, Fortress, Genfit, Gilead, Glympse, GlaxoSmithKline, Hepeon, High Tide, HistoIndex, Innovo, Intercept, Ionis, LG Chem, Lipocine, Madrigal, Medimmune, Merck, Mirum, NGM Biopharmaceuticals, Novo Nordisk, Novus Therapeutics, pH-Pharma, Sagimet, Target RWE, Theratechnologies and 89Bio; received institutional research grants from Allergan, Bristol Myers Squibb, Celgene, Cirius, Enanta, Genfit, Gilead, HighTide, Intercept, Madrigal and NGM Biopharmaceuticals; and has stock options in HepGene. K.K. has received grant/research/clinical trial support from Corcept, CymaBay, Genfit, Gilead, GlaxoSmithKline, Hanmi, Intercept, Madrigal, Mirum, Novo Nordisk, NGM Biopharmaceuticals, Pfizer, Pliant, Terns, Viking and 89Bio. He has served as consultant or on advisory boards for CymaBay, Enanta, Genfit, Gilead, HighTide, Inipharm, Intercept, Madrigal, Mirum, NGM Biopharmaceuticals, Pfizer and 89Bio. He serves on the speaker’s bureau for AbbVie, Gilead and Intercept and has stock options from Inipharm. R.V. receives institutional research grant support from Zydus Therapeutics, Galectin Therapeutics, Gilead Sciences, Novo Nordisk and Eli Lilly and also discloses consulting for LabCorp, GlaxoSmithKline, Medpace, GW Pharma, Daichi Sankyo and Echosens. C.B. has provided consulting or participated in seminars/preceptorships for Alimentev, Pfizer and Novo Nordisk. C.B.’s institution (Pacific Rim Pathology Laboratory/Analytic Pathology Medical Group) currently receives support for biopsy-related work through non-exclusive laboratory services and/or consulting agreements with Akero Therapeutics, Covance, E Study Site, Genesis Imaging Service, ICON, Medical Research Group and Southern California Research Center. J.T. has no conflicts to report. A.S. has provided consulting for General Electric and Gerson Lehman Group; is a member of the advisory or scientific boards for General Electric, Rhino Healthtech, Ochre Bio and FNIH; has received research support from Canon, Echosens, General Electric, Philips, Siemens and Supersonic Imagine/Hologic; has received research funding from Analogic Corporation, the US Department of Defense, Fujifilm Healthcare, FNIH and General Electric; and has equity in Avira, Autonomus, Evidence Based Psychology, Klea, Katharos Labs, Quantix Bio and Sonoluminous. C.S. reports research grants from ACR, Bayer, FNIH, GE, Gilead, Pfizer, Philips and Siemens; lab service agreements with Enanta, Gilead, ICON, Intercept, Nusirt, Shire, Synageva and Takeda; institutional consulting for Bristol Myers Squibb, Exact Sciences, IBM-Watson and Pfizer; personal consulting for Blade, Boehringer Ingelheim, Epigenomics and Guerbet; receipt of royalties and/or honoraria from Medscape and Wolters Kluwer; ownership of stock options in Livivos; and an unpaid advisory board position at Quantix Bio. C.S. has also been approved by his university to serve as Chief Medical Officer for Livivos (to be an unsalaried position with stock options). S.P.S. is an employee of Pfizer and has shares/stock options. K.F. reports institutional research support from Bayer, FNIH, GE, Gilead, Pfizer, Philips and Siemens; lab service agreements with Enanta, Gilead, ICON, Intercept, Nusirt, Shire, Synageva and Takeda; personal consulting from Bayer, GE and Epigenomics; and unpaid advisory board for Quantix Bio. H.H. has no conflicts to report. T.N.K. has no conflicts to report. R.L. serves as a consultant or advisory board member for 89Bio, Alnylam, Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Cirius, CohBar, DiCerna, Galmed, Gilead, Glympse Bio, Intercept, Ionis, Metacrine, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Sagimet and Viking Therapeutics. In addition, his institution has received grant support from Allergan, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galmed Pharmaceuticals, Genfit, Gilead, Intercept, Inventiva, Janssen, Madrigal Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Pfizer, pH Pharma and Siemens. He is also co-founder of Liponexus. R.A.C. is an employee of Regeneron Pharmaceuticals and owns stock in both Regeneron and Pfizer.